MedTrace Logo

Acute and Long-Term Antidepressant Treatment Success in Adolescents With Anxiety (AtLAS-A)

NCT04245436 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2024-08-29

No results posted yet for this study

Summary

Acute, double-blind, adaptively randomized treatment with duloxetine or escitalopram, followed by open-label naturalistic follow-up.

Conditions

Interventions

DRUG

Duloxetine

Encapsulated duloxetine 30 mg, 60 mg; once-daily

DRUG

Escitalopram

Encapsulated escitalopram 5 mg, 10 mg, 15 mg, 20 mg; once-daily

Sponsors & Collaborators

  • University of Cincinnati

    lead OTHER

Principal Investigators

  • Jeffrey R Strawn, MD · University of Cincinnati

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-01
Primary Completion
2025-07-31
Completion
2025-08-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04245436 on ClinicalTrials.gov